sirolimus and Macrophage-Activation-Syndrome

sirolimus has been researched along with Macrophage-Activation-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for sirolimus and Macrophage-Activation-Syndrome

Article	Year
Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome. Frontiers in immunology, 2018, Volume: 9 Gain of function (GOF) mutations affecting the inflammasome component NLRC4 are known to cause early-onset macrophage activation syndrome (MAS) and neonatal enterocolitis. Here we report a patient with a NLRC4 GOF mutation presenting with neonatal MAS efficiently treated with a combination of anakinra and rapamycin. Through Topics: Calcium-Binding Proteins; CARD Signaling Adaptor Proteins; Caspase 1; Female; Gain of Function Mutation; Humans; Interleukin-18; Interleukin-1beta; Macrophage Activation Syndrome; Sirolimus	2018

Article

Year

Rapamycin as an Adjunctive Therapy for NLRC4 Associated Macrophage Activation Syndrome.

Frontiers in immunology, 2018, Volume: 9

Gain of function (GOF) mutations affecting the inflammasome component NLRC4 are known to cause early-onset macrophage activation syndrome (MAS) and neonatal enterocolitis. Here we report a patient with a NLRC4 GOF mutation presenting with neonatal MAS efficiently treated with a combination of anakinra and rapamycin. Through

Topics: Calcium-Binding Proteins; CARD Signaling Adaptor Proteins; Caspase 1; Female; Gain of Function Mutation; Humans; Interleukin-18; Interleukin-1beta; Macrophage Activation Syndrome; Sirolimus

2018